The pattern of use of non‐steroidal anti‐inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Purpose: To describe the nationwide pattern of use of non‐steroidal anti‐inflammatory drugs (NSAIDs) in the Danish population. Methods: All Danish citizens aged 10 or above 1 January 1997 were included in the study. The national prescription registry was used to identify all claimed prescriptions for NSAIDs by the cohort until 2005. By individual‐level‐linkage of nationwide registries, information was acquired concerning hospitalizations, comorbidity, concomitant pharmacotherapy and socioeconomic factors. Results: The population consisted of 4 614 807 individuals, of which 2 663 706 (57.8%) claimed at least one prescription for NSAID from 1997 to 2005. Ibuprofen and diclofenac were the most frequently used non‐selective NSAIDs, whereas rofecoxib and celecoxib were the most frequently used selective cyclooxygenase‐2 (COX‐2) inhibitors. The usage was similar across all age groups. Female sex and increasing age was associated with increased use of NSAID. Factors predicting extensive NSAID use were: rheumatic disease (odds ratio (OR) = 1.79, 95% confidence interval (CI): 1.69–1.90), gout agents (allopurinol) (OR = 2.54, CI: 2.44–2.64) and other pain medication (OR = 3.27, CI: 3.23–3.31). NSAIDs were most often prescribed for use for one distinct treatment interval and for a short period (overall inter‐quartile range [IQR]: 9–66 days). High doses were used in a relatively large proportion of the population (8.9% for etodolac to 19.5% for celecoxib) and 54 373 (2.0%) claimed prescriptions for more than one NSAID at the same time. Conclusion: NSAIDs were commonly used in the Danish population. Since NSAIDs have been associated with increased cardiovascular risk, further research on the overall risk associated with these drugs on a national scale is needed. Copyright © 2008 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452 · cited 2×
“Hospital admissions were identified by ICD codes in the National Patient Registry according to the Charlson comorbidity index,(24) which was modified for use with the ICD-10.(25,26) Furthermore, we identified all individuals who received glucose-lowering medication (ATC code A10) the last 6 months of 1996 and defined…”
MethodCardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519 · cited 3×
“P rofecoxib and celecoxib, respectively).(2) However, results from the APPROVe study have been questioned and later analyses have demonstrated that the cardiovascular risk was present already after 3–6 months.”
BackgroundResultRisk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804
Cited by
Hansen, M. L., Sørensen, R., Clausen, M. T., Fog-Petersen, M. L., Raunsø, J., Gadsbøll, N., Gislason, G. H., Folke, F., Andersen, S. S., Schramm, T. K., et al. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.271 · Cited by 855
Cardiovascular effects and safety of (non-aspirin) NSAIDs
Schjerning, A.-M., McGettigan, P., & Gislason, G. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0366-z · Cited by 387
Self-citationSchjerning Olsen, A.-M., Fosbøl, E. L., Lindhardsen, J., Folke, F., Charlot, M., Selmer, C., Lamberts, M., Bjerring Olesen, J., Køber, L., Hansen, P. R., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004671 · Cited by 335
Self-citationXie, X., Ren, K., Zhou, Z., Dang, C., & Zhang, H. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02130-2 · Cited by 260
Schmidt, M., Lamberts, M., Olsen, A.-M. S., Fosbøll, E., Niessner, A., Tamargo, J., Rosano, G., Agewall, S., Kaski, J. C., Kjeldsen, K., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv505 · Cited by 164
Metadata
- Authors
- Fosbøl, E. L., Gislason, G. H., Jacobsen, S., Abildstrom, S. Z., Hansen, M. L., Schramm, T. K., Folke, F., Sørensen, R., Rasmussen, J. N., Køber, L., Madsen, M., & Torp‐Pedersen, C.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2008-03-28
- Volume
- 17
- Issue
- 8
- Pages
- 822-833
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W2146988769
- Cited by
- 144
- References
- 5
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.